Irwin Naturals Bringing Its Household Name Brand to the Psychedelic Mental Health SpaceTryp Therapeutics Announces Inclusion in AdvisorShares Psychedelics ETFMindMed and Liechti Lab Provide Results from their Psilocybin R&D CollaborationPsyched Wellness Announces Inclusion in AdvisorShares Psychedelics Exchange Traded Fund (ETF)Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in Eating DisordersPsyched Wellness Initiates a Clinical Sleep Study on Humans for a Structure/Function Claim For AME-1Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst as Indications for MSP-1014, its NoveHow Will The Data Protection Ruling On Ketamine Impact Psychedelic Novel Drug Development Moving Forward?Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic AnalogsSilo Pharma Advances Psychedelic Patent PortfolioTryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of FloridaMajor Psychedelic Clinical Trial Data Is Right Around The CornerPsychedelic Drug Development Companies Are Leveraging Bolt On MedTech Acquisitions To Create A More Robust Patient Care 7 Psychedelic Clinical Trials Underway That Investors Should Keep On Their RadarNuminus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into PSilo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide PatentTryp Therapeutics Announces Q3 2021 Financial ResultsKetamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured VeteransWake Network, Inc. and the Lieber Institute for Brain Development Announce Research CollaborationTryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia with the University of Michigan

Technical420 Site Search

Returned 12 result(s).

HAVN Life Sciences Continues To Execute On Growth Initiatives Ahead Of Its Upcoming Public Listing

We have seen a substantial increase in interest in psychedelic focused businesses during the last month and this is a trend that our readers need to be aware of. The psychedelic sector has recently come under pressure and we encourage our readers to conduct significant due diligence on companies in…

HAVNLife Is A Diversified Psychedelics Play Investors Need To Have On Their Radar

Earlier this year, we conducted significant due diligence on the emerging psychedelic market and believe that it is a vertical that is starting to gain traction. Like cannabis in 2014, the psychedelic industry is in the early stages of what is expected to be a major growth cycle. We are…

« Newer Posts

Search Again

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link